Department of Pharmacy, College of Medicine and Health Science, Wollo University, Dessie, Ethiopia.
Department of Pharmacy, College of Medicine and Health Science, Debre Berhan University, Debre Berhan, Ethiopia.
PLoS One. 2021 Mar 5;16(3):e0247777. doi: 10.1371/journal.pone.0247777. eCollection 2021.
HIV/AIDS remains a public health concern affecting millions of people across the world. Although the health-related quality of life (HRQoL) of patients living with HIV has significantly improved after treatment, its chronicity makes the HRQoL uncertain. This study assessed factors associated with the health-related quality of life among people living with HIV/AIDS on HAART in North-East Ethiopia.
An institutional-based cross-sectional study was conducted from March to April 2018, and systematic random sampling was used to select 235 participants who were on HAART. HRQoL was assessed using the Medical Outcomes Study HIV Health Survey. Descriptive and multiple linear regression analysis were computed using the statistical package for social sciences version 20.
The study revealed one-factor structure and had good overall internal consistency (78.5). Over one-third (42.6%; 95% CI; 36.2%, 48.9%) of participants had good HRQoL. The least HRQoL mean score was found for cognitive functioning 32.21(±19.78), followed by social functioning 40.58(±29.8). Factors associated with the overall HRQoL were 25-45 years of age (β = - 3.55, 95% CI;-6.54, -0.55), working in private sector (β = -5.66, 95% CI;-9.43, -1.88), government (β = -4.29, 95% CI;-7.83, -0.75) and self-employment (β = -8.86, 95% CI;-13.50, -4.21), 100-200 (β = - 4.84, 95% CI;-9.04, -0.63) and 201-350 CD4 at the time of diagnosis (β = - 7.45, 95% CI;-11.73, -3.16), 351-500 current CD4 level (β = 8.34, 95% CI;5.55, 11.41), 6-10 years of disease duration (β = -8.28, 95% CI;-12.51, -4.04), WHO stage II (β = -4.78, 95% CI;-8.52, -1.04) and III (β = 3.42, 95% CI;0.06, 6.79) during treatment initiation and not taking of Cotrimoxazole prophylaxis (β = -5.79, 95% CI;-8.34, -3.25).
High proportion of participants had a poor HRQoL. Routine assessment and appropriate interventions at each visit is recommended to improve HRQoL.
艾滋病仍然是一个影响全球数百万人的公共卫生问题。尽管接受治疗后，艾滋病毒感染者的健康相关生活质量（HRQoL）有了显著改善，但由于其慢性特点，HRQoL 仍然不确定。本研究评估了在埃塞俄比亚东北部接受抗逆转录病毒治疗（HAART）的艾滋病毒感染者与健康相关的生活质量相关因素。
本研究为 2018 年 3 月至 4 月进行的基于机构的横断面研究，采用系统随机抽样方法选择了 235 名正在接受 HAART 的参与者。使用医疗结果研究艾滋病毒健康调查评估 HRQoL。使用社会科学统计软件包 20 计算描述性和多重线性回归分析。
该研究揭示了一种单一因素结构，且具有良好的整体内部一致性（78.5%）。超过三分之一（42.6%；95%置信区间；36.2%，48.9%）的参与者具有良好的 HRQoL。认知功能的最低 HRQoL 平均得分为 32.21（±19.78），其次是社会功能 40.58（±29.8）。与总体 HRQoL 相关的因素包括 25-45 岁（β=-3.55，95%置信区间；-6.54，-0.55）、在私营部门工作（β=-5.66，95%置信区间；-9.43，-1.88）、政府（β=-4.29，95%置信区间；-7.83，-0.75）和自雇（β=-8.86，95%置信区间；-13.50，-4.21）、100-200（β=-4.84，95%置信区间；-9.04，-0.63）和 201-350 CD4 诊断时（β=-7.45，95%置信区间；-11.73，-3.16）、351-500 当前 CD4 水平（β=8.34，95%置信区间；5.55，11.41）、6-10 年疾病持续时间（β=-8.28，95%置信区间；-12.51，-4.04）、WHO 疾病分期 II（β=-4.78，95%置信区间；-8.52，-1.04）和 III（β=3.42，95%置信区间；0.06，6.79）在治疗开始时和未服用复方新诺明预防时。
大多数参与者的 HRQoL 较差。建议在每次就诊时进行常规评估和适当干预，以提高 HRQoL。
